ReviewEuropean journal of nuclear medicine and molecular imaging2013
Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations.
Review in European journal of nuclear medicine and molecular imaging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.
- Diagnostic value of dual-tracer PET/CT with [Frontiers in medicine · 2025Pooled it
- [Significance of PSMA imaging in prostate cancer].Der Urologe. Ausg. A · 2017Trial
- Dual-tracer positron emission tomography-computed tomography withQuantitative imaging in medicine and surgery · 2026Article
- Head-to-head comparison betweenJournal of translational medicine · 2026Article
- Metastatic Prostate Cancer with Pulmonary Involvement Mimicking Pneumonia: Findings onMolecular imaging and radionuclide therapy · 2026Article
- Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer.Molecules (Basel, Switzerland) · 2026Article
- Article
- Role of PSMA PET/CT in imaging and management of prostate cancer.Current opinion in oncology · 2025Review
- The Development of AlPharmaceutics · 2025Article
- Head-to-head comparison ofFrontiers in oncology · 2025Article
- Description of FDG and Prostate-Specific Membrane Antigen PET/CT Findings in Korean Patients With Advanced Metastatic Castration-Resistant Prostate Cancer.Korean journal of radiology · 2024Article
- Discordant Molecular Imaging Findings with 2-[Nuclear medicine and molecular imaging · 2024Article
- Unexpected focal fluorodeoxyglucose uptake in main organs; pass through or pass by?World journal of clinical cases · 2024Review
- Radiotheranostics in advanced prostate cancer: Current and future directions.Prostate cancer and prostatic diseases · 2024Review
- Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy.Annals of nuclear medicine · 2024Article
- Tracing prostate cancer - the evolution of PET-CT applications.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Review
- Molecular imaging reveals the heterogeneous progression of tumor cells and tumor stroma: a practice of FDG PET and FAPI PET in diagnosing PSMA-negative bone metastases of progressive prostate cancer.American journal of nuclear medicine and molecular imaging · 2024Article
- Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study.Therapeutic advances in medical oncology · 2024Article
- Article
- Up-to-Date Imaging and Diagnostic Techniques for Prostate Cancer: A Literature Review.Diagnostics (Basel, Switzerland) · 2023Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Prostate cancer is a major public health problem in developed countries. The remarkable biological and clinical heterogeneity of prostate cancer provides unique opportunities as well as challenges for the diagnostic imaging evaluation of this prevalent disease. The disease is characterized by a natural history that ranges from localized slowly growing hormone-dependent tumor progressing to metastatic hormone-refractory disease. PET is an ideal imaging tool for noninvasive interrogation of the underlying tumor biology. (18)F-FDG is the most common PET radiotracer used for oncological applications based upon elevated glucose metabolism in malignant tissue in comparison to normal tissue. FDG uptake in prostate cancer depends on tumor differentiation with low accumulation in well-differentiated tumors and high uptake in aggressive poorly differentiated tumors. Cumulative current evidence suggests that FDG PET may be useful in detection of disease in a small fraction of patients with biochemical recurrence, in the imaging evaluation of extent and treatment response in metastatic disease and in prediction of patient outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.